Table 2.
Ongoing and proposed new trials in ACC
| Drug | Target | Study phase | Tumor type | Mechanism of action |
|---|---|---|---|---|
| Avelumab (NCT01772004) | PD-L1 | I | Solid tumors including ACC | Immunotherapy |
| Ipilimumab + radiotherapy (NCT02239900) | CTLA-4 | I/II | Solid tumors including ACC | Immunotherapy |
| Pembrolizumab* (pre-accrual) | PD-L1 | II | ACC | Immunotherapy |
| ATR-101 (NCT01898715) | ACAT-1 | I/II | ACC | Inhibition of cholesterol esterification |
| BBI608 + paclitaxel (NCT01325441) | Cancer stem cell inhibitor | I/II | Solid tumors including ACC | Inhibition of Stat 3, β catenin and Nanog pathways |
*Proposed trials at Memorial Sloan Kettering and at University of Texas MD Anderson Cancer Center